Terumo Thailand
Terumo Thailand is the Thai subsidiary of Terumo Corporation (TSE: 4543), a Japanese medical-device manufacturer specialising in cardiovascular, infusion therapy, transfusion, diabetes care, and interventional systems. Terumo's Thai operations cover sales and distribution of its core product lines including SURFLO IV catheters, infusion pumps, blood-bag systems, glucose monitoring devices, and cardiac-surgery perfusion equipment to private hospital groups (BDMS, Bumrungrad) and public hospital networks. Terumo is a significant supplier to Thai hospitals given Japan's long-standing medical-device trade relationship with Thailand and Terumo's strong cardiovascular and infusion market positions across ASEAN. The company operates under Thai FDA medical-device registration requirements and competes with BD, B. Braun, and Baxter for infusion and vascular-access market share.
Profile overview
Terumo Thailand is the Thai subsidiary of Terumo Corporation (TSE: 4543), a Japanese medical-device manufacturer specialising in cardiovascular, infusion therapy, transfusion, diabetes care, and interventional systems. Terumo's Thai operations cover sales and distribution of its core product lines including SURFLO IV catheters, infusion pumps, blood-bag systems, glucose monitoring devices, and cardiac-surgery perfusion equipment to private hospital groups (BDMS, Bumrungrad) and public hospital networks. Terumo is a significant supplier to Thai hospitals given Japan's long-standing medical-device trade relationship with Thailand and Terumo's strong cardiovascular and infusion market positions across ASEAN. The company operates under Thai FDA medical-device registration requirements and competes with BD, B. Braun, and Baxter for infusion and vascular-access market share.
Product segments
Infusion and vascular access
SURFLO IV catheters and infusion pumps
Terumo's SURFLO IV catheter is among the most widely used peripheral vascular access devices in Thai hospitals. Infusion therapy products — sets, pumps, and extension lines — are distributed to BDMS group hospitals, Bumrungrad, and public hospital networks via authorised distributors.
Cardiovascular
Cardiac surgery and interventional systems
Terumo's cardiovascular segment supplies heart-lung bypass systems, blood bags, haemoconcentrators, and arterial filters to Thai cardiac surgery centres. Bumrungrad and BDMS Bangkok Heart Hospital are key end-user accounts. Japan-ASEAN cardiac-surgery growth underpins this segment.
Diabetes care
Glucose monitoring and insulin delivery
Terumo's diabetes-care line covers glucose monitors, insulin syringes, and pen needles. Thailand's approximately 4.5 million diagnosed diabetics represent a large addressable market. Competition from Abbott FreeStyle Libre and Roche Accu-Chek constrains premium pricing.
Transfusion
Blood-bag and processing systems
Terumo supplies blood-bag collection systems and automated blood-component separators to Thai Red Cross and hospital blood banks. This segment benefits from Thailand's active blood donation infrastructure and steady hospital-level procurement contracts.
Medical-device peer comparison — Thailand distribution
Origin
Japan
Key segments
Infusion, cardiovascular, diabetes
Ticker
TSE:4543
BD (Becton Dickinson)
Origin
USA
Key segments
Infusion, diagnostics, surgical
Ticker
NYSE:BDX
B. Braun Thailand
Origin
Germany
Key segments
Infusion, dialysis, surgical
Ticker
Private
Baxter Thailand
Origin
USA
Key segments
Dialysis, IV fluids, ICU
Ticker
NYSE:BAX
Nipro Thailand
Origin
Japan
Key segments
Dialysis, syringes, infusion
Ticker
TSE:8086
| Company | Origin | Key segments | Ticker |
|---|---|---|---|
| Terumo Thailand | Japan | Infusion, cardiovascular, diabetes | TSE:4543 |
| BD (Becton Dickinson) | USA | Infusion, diagnostics, surgical | NYSE:BDX |
| B. Braun Thailand | Germany | Infusion, dialysis, surgical | Private |
| Baxter Thailand | USA | Dialysis, IV fluids, ICU | NYSE:BAX |
| Nipro Thailand | Japan | Dialysis, syringes, infusion | TSE:8086 |
Watchpoints 2025–2026
US tariffs
19% US tariff impact on Thai exports
Thailand's medical-device exports to the US — approximately 25% of total — face a 19% US reciprocal tariff announced in 2025. Terumo's Thailand facility exports certain product lines; the tariff changes Thai production economics relative to Malaysian or Vietnamese alternatives.
EU CSDDD
Supply-chain due-diligence compliance
The EU Corporate Sustainability Due Diligence Directive (CSDDD) imposes traceability and human-rights audit obligations on Thai medical-device suppliers to EU buyers. Terumo Thailand must pass Terumo Corporation's group-level CSDDD audit framework to protect EU market access.
Digital health
AI and connected-device integration
Thai private hospitals are piloting AI-assisted infusion pumps and connected glucose-monitoring devices. Terumo's Medicalis remote ICU monitoring solution and CGM pipeline position it for integration, but hospital IT procurement cycles in Thailand are long at 12–24 months.
Source-pack context
Terumo Thailand is linked to existing Insight report coverage through tracked source packs. The cited sources provide the current evidence trail for market context, regulatory exposure, operator positioning, or sector structure; exact numeric claims should still be checked against raw snapshots before being surfaced as headline metrics.[, , ]
Deep operating read
Terumo Thailand is the Thai subsidiary of Terumo Corporation (TSE: 4543), a Japanese medical-device manufacturer specialising in cardiovascular, infusion therapy, transfusion, diabetes care, and interventional systems. In the linked report, it is positioned as Japanese-affiliated; medical-device, dialysis. What's market mix, watchpoints? Per Bangkok Post: Major export: US (~25%), EU (~20%), Japan, Korea (~15%), ASEAN (~15%), GCC, Africa, Latin America (~25%). Watchpoints: EU CSDDD compliance, US 19% tariff impact, Halal medical-device export expansion, AI-enabled medical-device, digital-health integration, Thai-medical-tourism intersection.[, , ]
Execution watchpoints
What's market mix, watchpoints? Watchpoints: EU CSDDD compliance, US 19% tariff impact, Halal medical-device export expansion, AI-enabled medical-device, digital-health integration, Thai-medical-tourism intersection. Watchpoints: EU CSDDD, US 19% tariff, AI, digital-health integration. Thai medical-device moat is foreign-affiliated tier-1 manufacturer concentration, BOI med-tech promotion, EEC industrial-cluster, Halal medical-device export, Thai-medical-tourism intersection. Watch EU CSDDD compliance, US 19% tariff impact, Halal medical-device export expansion (ASEAN, GCC), AI-enabled medical-device, digital-health integration as 2026-2028 leading indicators.[]
Related Market profiles
Peers, parents, partners, agencies, and other Medical Devices actors.
Competitor
Sri Trang Gloves
World top-5 medical, exam glove manufacturer; vertically integrated via Sri Trang Agro-Industry parent; FY2024 revenue ~ $782.6M.
Open Market profile →
Competitor
Abbott Thailand
US-parent MNC diagnostics, CGM, nutrition, cardiovascular; FreeStyle Libre anchor; ~6% Thai medical-device market share.
Open Market profile →
Competitor
Becton Dickinson Thailand (BD Thailand)
Thai subsidiary of Becton Dickinson (NYSE: BDX); distributes and markets BD's medical devices, diagnostics, and life-science products across the Thai healthcare market.
Open Market profile →
Sector peer
Bionova Thailand
Thai distributor and representative of in-vitro diagnostic and medical-device products serving hospitals and clinical laboratories across Thailand.
Open Market profile →
Reports featuring this profile
Related Market profiles
competitor
Sri Trang Gloves
World top-5 medical, exam glove manufacturer; vertically integrated via Sri Trang Agro-Industry parent; FY2024 revenue ~THB 27B.
competitor
Abbott Thailand
US-parent MNC diagnostics, CGM, nutrition, cardiovascular; FreeStyle Libre anchor; ~6% Thai medical-device market share.
competitor
Becton Dickinson Thailand (BD Thailand)
Thai subsidiary of Becton Dickinson (NYSE: BDX); distributes and markets BD's medical devices, diagnostics, and life-science products across the Thai healthcare market.